Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 16;24(1):559.
doi: 10.1186/s13054-020-03273-y.

Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations

Adam Flaczyk  1 , Rachel P Rosovsky  2 , Clay T Reed  3 , Brittany K Bankhead-Kendall  4 , Edward A Bittner  1 , Marvin G Chang  5
Affiliations
Review

Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations

Adam Flaczyk et al. Crit Care. .

Abstract

Critically ill patients with COVID-19 are at increased risk for thrombotic complications which has led to an intense debate surrounding their anticoagulation management. In the absence of data from randomized controlled clinical trials, a number of consensus guidelines and recommendations have been published to facilitate clinical decision-making on this issue. However, substantive differences exist between these guidelines which can be difficult for clinicians. This review briefly summarizes the major societal guidelines and compares their similarities and differences. A common theme in all of the recommendations is to take an individualized approach to patient management and a call for prospective randomized clinical trials to address important anticoagulation issues in this population.

Keywords: Anticoagulation; COVID-19; Coronavirus; Hematologic monitoring; Therapeutic anticoagulation; Thrombosis; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

RR is on the Board of Directors for the Pulmonary Embolism Response Team (PERT) Consortium and has no other competing interests as it relates to this manuscript. All other authors declare to have no competing interests.

References

    1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi: 10.1182/blood.2020006000. - DOI - PMC - PubMed
    1. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858. doi: 10.1093/eurheartj/ehaa254. - DOI - PMC - PubMed
    1. Martinelli I, Ferrazzi E, Ciavarella A, et al. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res. 2020;191:36–37. doi: 10.1016/j.thromres.2020.04.022. - DOI - PMC - PubMed
    1. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med. 2020;382(17):e38. doi: 10.1056/NEJMc2007575. - DOI - PMC - PubMed
    1. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection. Blood. 2020;136(4):489–500. - PMC - PubMed